Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia (AML) (Protocol Number: 2449-US-002)
This study has been terminated.
(Failure to demonstrate a tolerable dose that had potential for efficacy.)
Kyowa Hakko Kirin Pharma, Inc.
First Posted: October 24, 2008
Last Update Posted: June 15, 2016
Information provided by (Responsible Party):
Kyowa Kirin Pharmaceutical Development, Inc. ( Kyowa Hakko Kirin Pharma, Inc. )